An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

To be considered for this study, you must have already taken part in and finished an earlier study called 'Study 301' for the same medicine, ALXN2220. This means you would have completed all parts of that previous study, including the final check-up.

There are also some reasons why you might not be able to join. For example, if you stopped taking the study medicine in the previous study, or if you completely withdrew your consent from Study 301, you wouldn't be able to participate. Also, if you have known allergies to proteins or any ingredients in ALXN2220, or if you've had a heart transplant or certain heart device implants, you would not be able to join. Doctors will also check for any new or worsening health issues that might make it unsafe for you to take part.

If you join this study, you will continue to receive the study medicine, ALXN2220, along with your usual heart care. Because this is a follow-on study, the exact details of what your participation involves will be explained by the study team, building on your experience from the previous study (Study 301). This will typically include regular visits to the clinic for health checks, blood tests, and other assessments to see how the medicine is working and to monitor your health. The study team will track your progress over a long period to understand the long-term effects of ALXN2220. They will give you full details about the number of visits, tests, and how long you will be involved.